Zhejiang Zhenyuan announced that in the first half of 2026, net profit loss attributable to shareholders of listed companies is expected to be 11 million yuan to 16 million yuan, down 119.55% to 128.44% from 56.2637 million yuan in the same period last year; net profit loss after deducting non-recurring profit and loss is 18 million yuan to 23 million yuan, down 159.77% to 176.37% from 30.1173 million yuan in the same period last year. Reasons for changes in performance: The investment intensity of the Zhenyuan Biotech project is high and production costs are high; the traditional sector is affected by pharmaceutical collection, medical insurance fees, and increased competition in the industry, and sales revenue and gross profit declined; tax self-inspection and payment of taxes and late fees; and increased financial expenses due to continued investment in project construction.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.